EVGN.US Evogene

Healthcare Biotechnology USA Stocks
0.3710 USD
Close of Nov 14, 2026
0.2500 1.26
Market cap
USD 6.70M
P/E
-
P/B
4.71x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is EVGN.US undervalued?

Graham number

The Graham number of Evogene cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Evogene fundamental analysis

No fundamental analysis for Evogene yet.

Evogene stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the dev…

Full company profile